◆英語タイトル:Intas Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012303
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月14日
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Intas Pharmaceuticals Ltd (Intas) develops, manufactures, and markets pharmaceuticals and biotechnology products for the treatment of a wide range of diseases and disorders in various therapeutic segments. The company offers products such as sevelamer, ciprofloxacin, amitryptyline, erythropoietin, filgrastim, follicle stimulating hormone (FSH), rituximab, ampicillin, albendazole, benezepril, and caprofen, among others. It also develops recombinant DNA protein (rDNA) products and plasma derived products for oncology, auto-immune, ophthalmology, nephrology, and plasma derived product based therapies. It has nine formulation manufacturing facilities and two active pharmaceutical ingredient (API) and intermediate facilities in India. The company markets its products globally through internal sales force and a network of distributors. Intas is headquartered in Ahmedabad, Gujarat, India.
Intas Pharmaceuticals Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Intas Pharmaceuticals Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Teva Pharma May Sell European Oncology and Pain Assets 13
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 15
Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare 16
Intas Pharma to Acquire Gujarat-based Biotechnology Unit of RPG Life Sciences for USD3.7 Million 18
Intas Pharma Acquires Hospital Business of Combino Pharm 19
Private Equity 20
Capital International Acquires 3% Stake in Intas Pharma from ChrysCapital for USD106 Million 20
Temasek Acquires 10.16% Stake in Intas Pharma for USD143 Million 21
ChrysCapital Acquires Additional 7.5% Stake In Intrys Phrama For US$56.1 Million 22
ChrysCapital Acquires Additional 2.53% Stake In Intas Pharma For US$56 Million 23
Partnerships 24
Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 24
Licensing Agreements 25
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 25
Phosphagenics Enters Into Licensing Agreement With Intas Pharma For Anti-Ageing Products 26
Equity Offering 27
Intas Pharma Files Registration Statement For IPO To Raise Up To US$200 Million 27
Acquisition 28
Accord Healthcare Acquires Essential Pharma 28
Intas Pharmaceuticals Ltd – Key Competitors 29
Intas Pharmaceuticals Ltd – Key Employees 30
Intas Pharmaceuticals Ltd – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34
List of Tables
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Intas Pharmaceuticals Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Intas Pharmaceuticals Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Intas Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Teva Pharma May Sell European Oncology and Pain Assets 13
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 15
Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare 16
Intas Pharma to Acquire Gujarat-based Biotechnology Unit of RPG Life Sciences for USD3.7 Million 18
Intas Pharma Acquires Hospital Business of Combino Pharm 19
Capital International Acquires 3% Stake in Intas Pharma from ChrysCapital for USD106 Million 20
Temasek Acquires 10.16% Stake in Intas Pharma for USD143 Million 21
ChrysCapital Acquires Additional 7.5% Stake In Intrys Phrama For US$56.1 Million 22
ChrysCapital Acquires Additional 2.53% Stake In Intas Pharma For US$56 Million 23
Albany Molecular Research Enters into Agreement with Grupo Ferrer and Accord Healthcare 24
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 25
Phosphagenics Enters Into Licensing Agreement With Intas Pharma For Anti-Ageing Products 26
Intas Pharma Files Registration Statement For IPO To Raise Up To US$200 Million 27
Accord Healthcare Acquires Essential Pharma 28
Intas Pharmaceuticals Ltd, Key Competitors 29
Intas Pharmaceuticals Ltd, Key Employees 30
Intas Pharmaceuticals Ltd, Other Locations 31
Intas Pharmaceuticals Ltd, Subsidiaries 32